MicroPort CardioFlow Medtech 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jeffrey R Lindstrom

최고 경영자

CN¥4.0m

총 보상

CEO 급여 비율	59.8%
CEO 임기	1.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	4yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jeffrey R Lindstrom 의 보수는 MicroPort CardioFlow Medtech 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥349m
Mar 31 2024	n/a	n/a	-CN¥410m
Dec 31 2023	CN¥4m	CN¥2m	-CN¥472m

보상 대 시장: Jeffrey R 의 총 보상 ($USD 562.75K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 816.84K ).

보상과 수익: Jeffrey R 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Jeffrey R Lindstrom (57 yo)

1.2yrs

테뉴어

CN¥4,004,000

보상

Mr. Jeffrey R Lindstrom is President, Executive Director & General Manager of MicroPort CardioFlow Medtech Corporation from August 29, 2023. He served as senior director of engineering in Edwards Lifescien...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jeffrey R Lindstrom	President	1.2yrs	CN¥4.00m	데이터 없음
Liang Zhao	Executive Director & First VP of Total Solutions	2.4yrs	CN¥3.91m	0.058% € 123.6k
Luying Yan	VP & Executive Director	4.1yrs	CN¥2.70m	0.042% € 88.8k
Xiangmei Li	Joint Company Secretary	4yrs	데이터 없음	데이터 없음
Lok Yee Chan	Joint Company Secretary	4yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

43yo

평균 연령

경험이 풍부한 관리: 72X 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jeffrey R Lindstrom	President	1.2yrs	CN¥4.00m	데이터 없음
Liang Zhao	Executive Director & First VP of Total Solutions	2.4yrs	CN¥3.91m	0.058% € 123.6k
Luying Yan	VP & Executive Director	4.1yrs	CN¥2.70m	0.042% € 88.8k
Jonathan H. Chou	Independent Non-Executive Director	3.8yrs	CN¥254.00k	데이터 없음
Xia Wu	Non-Executive Director	5.2yrs	데이터 없음	데이터 없음
Guoming Chen	Non-Executive Chairman of the Board	4.1yrs	CN¥3.16m	0.031% € 65.1k
Junjie Zhang	Non-Executive Director	5.2yrs	데이터 없음	데이터 없음
Zhixiang Sun	Independent Non-Executive Director	3.8yrs	CN¥254.00k	데이터 없음
Jiandong Ding	Independent Non-Executive Director	3.2yrs	CN¥254.00k	0.0012% € 2.6k

3.8yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 이사회: 72X 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

MicroPort CardioFlow Medtech 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Recent updates

Now 22% undervalued after recent price drop

Now 28% undervalued

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.076 loss in 1H 2023)

Now 56% undervalued after recent price drop

MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024

Now 48% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

Forecast to breakeven in 2026

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.19 loss in FY 2022)

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC System

MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in Europe

MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI Product

First half 2023 earnings released: CN¥0.076 loss per share (vs CN¥0.052 loss in 1H 2022)

MicroPort Cardioflow Medtech Corporation Announces Executive Changes

MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.079 loss in FY 2021)

Less than half of directors are independent

Microport Cardioflow Medtech Corporation Announces Registration in Colombia for Alwide Plus Balloon Catheter

First half 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.031 loss in 1H 2021)

MicroPort CardioFlow Medtech Corporation to Report Q2, 2022 Results on Aug 29, 2022

MicroPort CardioFlow Medtech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Microport Cardioflow Medtech Corporation Announces That the Transcatheter Mitral Valve Replacement System Independently Developed by the Group Was Successfully Applied by the Heart Team of Zhongshan Hospital

MicroPort CardioFlow Medtech Announces Appointment of Zhao Liang as Executive Director

Full year 2021 earnings released: CN¥0.079 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation Announces Resignation of Wu Guojia as an Executive Director

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.23 loss in FY 2020)

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 22, 2022

Microport Cardioflow Medtech Corporation Successfully Registered Vitaflow Liberty Transcatheter Aortic Valve Implantation System in Argentina

Microport Cardioflow Medtech Corporation Announces Ce Mark Registration Application for Vitaflow Libertytm

No longer forecast to breakeven

Forecast to breakeven in 2023

Independent Non-Executive Director Hualiang Jiang has left the company

MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령